Keymed Bio-B (02162): Kangyueda revenue for the first three quarters totaled approximately RMB 660 million, a year-on-year increase of approximately 227%.

Zhito Finance APP News, Keymed Bio-B (02162) announced that the revenue of the Company's product Kangyueda (IL-4R monoclonal antibody, stapokibart) for the first three quarters of 2026 totaled approximately RMB 660 million, representing a year-on-year increase of approximately 227%. The core drivers came from genuine market demand and a sharp increase in the number of hospitals with access. Thanks to the support of national policies, as of January 1, 2026, Kangyueda's three approved indications for adults with moderate-to-severe atopic dermatitis (AD), chronic rhinosinusitis with nasal polyps (CRSwNP), and seasonal allergic rhinitis (SAR), as well as its two packaging formsvials and pre-filled autoinjectorshave all been included in China's National Reimbursement Drug List, with a medical insurance payment standard of RMB 1,039 per unit (specification: 300mg/2ml), greatly improving affordability for Chinese patients. Meanwhile, in July 2026, Kangyueda was officially included in the National Essential Medicines List (2026 Edition), effective from September 1, 2026. According to relevant regulations on essential medicines, public medical institutions at all levels nationwide are required to stock and give priority to the use of medicines on the list, further broadening terminal prescription scenarios and enhancing drug accessibility.